Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1817-1830

  Lim, Kyoung Soo ^a   Kim, Jung Ryul ^a   Choi, Yun Jung ^a   Shin, Kwang Hee ^a   Kim, Kyu Pyo ^a   Hong, Jang Hee ^a   Cho, Joo Youn ^a   Shin, Hyun Suk ^a   Yu, Kyung Sang ^a   Shin, Sang Goo ^a   Kwon, O Hwan ^b   Hwang, Dal Mi ^b   Kim, Jeong Ae ^b   Jang, In Jin ^a  

^a Seoul National University College of Medicine   (South Korea)

^b LG Chemical Ltd   (South Korea)

Author keywords

biomarker; DPP IV; LC15 0444; pharmacodynamics; pharmacokinetics

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LC 150444; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDICATION; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; ECG ABNORMALITY; ENZYME ACTIVITY; EPISTAXIS; FOOD; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY CLEARANCE; KOREAN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; NOSE CONGESTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SORE THROAT; SYSTEMATIC REVIEW; TANDEM MASS SPECTROMETRY; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HUMANS; INSULIN; KOREA; MALE; METABOLIC CLEARANCE RATE; ORGANIC CHEMICALS; YOUNG ADULT;

EID: 55949101857     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.013     Document Type: Article

References (17)

1. Drucker D.J., and Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
2. Flock G., Baggio L.L., Longuet C., and Drucker D.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007) 3006-3013
3. Ahren B., Simonsson E., Larsson H., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
4. Pei Z. From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel 11 (2008) 512-532
5. LG Life Sciences Ltd. (2007). Clinical Study Report. LGDPCL001. Seoul, Republic of Korea.
6. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
7. *) versus REMEDI-HS. J Anal Toxicol 31 (2007) 321-327
8. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 (October 27, 2007). http://www.wma.net/e/policy/b3.htm Accessed
9. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78 (2005) 675-688
10. Krikken J.A., Lely A.T., Bakker S.J., and Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 71 (2007) 260-265
11. Demuth H.U., McIntosh C.H., and Pederson R.A. Type 2 diabetestherapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751 (2005) 33-44
12. Bergman A.J., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A doubleblind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 (2006) 55-72
13. Ritzel R., Orskov C., Holst J.J., and Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38 (1995) 720-725
14. Woosley R.L., and Cossman J. Drug development and the FDA's Critical Path Initiative. Clin Pharmacol Ther 81 (2007) 129-133
15. Wagner J.A., Williams S.A., and Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81 (2007) 104-107
16. Herman G.A., Stein P.P., Thornberry N.A., and Wagner J.A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin. Clin Pharmacol Ther 81 (2007) 761-767
17. Herman G.A., Bergman A., Liu F., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46 (2006) 876-886